...
首页> 外文期刊>Journal of Thoracic Disease >Stem cell therapies for chronic obstructive pulmonary disease: current status of pre-clinical studies and clinical trials
【24h】

Stem cell therapies for chronic obstructive pulmonary disease: current status of pre-clinical studies and clinical trials

机译:慢性阻塞性肺疾病的干细胞疗法:临床前研究和临床试验的现状

获取原文
           

摘要

Chronic obstructive pulmonary disease (COPD) is a respiratory disease that has a major impact worldwide. The currently-available drugs mainly focus on relieving the symptoms of COPD patients. Novel regenerative therapeutic approaches have been investigated with the aim of repairing or replacing the injured functional structures of the respiratory system. We summarized the progress made by regenerative therapies for COPD by analyzing results from both pre-clinical studies and completed clinical trials. These approaches include the application of exogenous stem cells or small molecules to stimulate the regeneration by endogenous lung stem/progenitor cells. Exogenous mesenchymal stem cells (MSCs) have been reported to repair the structure and improve the function of the injured respiratory system in COPD models. However, the studies that used MSCs in patients with moderate-to-severe COPD patients did not lead to clear respiratory functional improvements. Exogenous human lung stem cells applied to cryo-injured (CI) lungs of mice have been shown to organize into human-like pulmonary structures, indicating a new property of stem cells that is potentially capable of curing COPD patients. Small molecules like retinoic acid has been shown to lead to regeneration and repair of the damaged lung structures in COPD mouse models probably by activation of endogenous lung stem/progenitor cells. However, retinoic acid or agonists of retinoic acid receptor administered to moderate or severe COPD patients did not improve the density and function of the damaged lung. These novel regenerative approaches have failed in preliminary clinical trials, possibly due to the advanced severity of the disease. Further work should be done to develop the current regenerative approaches for curing patients at different stages of COPD. We suggest that some modifications of the approach in the clinical studies may lead to more successful outcomes of regenerative therapy for COPD.
机译:慢性阻塞性肺疾病(COPD)是一种呼吸系统疾病,在世界范围内具有重大影响。目前可用的药物主要集中于减轻COPD患者的症状。为了修复或替换受损的呼吸系统功能结构,已经研究了新型的再生治疗方法。我们通过分析临床前研究和已完成的临床试验的结果,总结了COPD再生疗法的进展。这些方法包括应用外源性干细胞或小分子刺激内源性肺干/祖细胞的再生。据报道,在COPD模型中,外源性间充质干细胞(MSC)可修复结构并改善受损呼吸系统的功能。但是,在中重度COPD患者中使用MSC的研究并未导致明显的呼吸功能改善。已经显示,应用于小鼠冷冻损伤(CI)肺的外源性人类肺干细胞可组织成类似人的肺部结构,这表明干细胞的一种新特性可以潜在地治愈COPD患者。已经显示,像维甲酸这样的小分子可能会通过激活内源性肺干/祖细胞来导致COPD小鼠模型中受损肺结构的再生和修复。然而,向中度或重度COPD患者施用视黄酸或视黄酸受体激动剂并不能改善受损肺的密度和功能。这些新的再生方法在初步临床试验中失败了,可能是由于疾病的严重程度所致。应该做进一步的工作来开发当前的再生方法,以治愈处于COPD不同阶段的患者。我们建议在临床研究中对该方法进行一些修改可能会导致COPD再生治疗取得更成功的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号